| Literature DB >> 34843084 |
Christina Theodore-Oklota1, Deborah S Hartman2, Deborah L Hoffman3, Hans T Björnsson4,5,6.
Abstract
INTRODUCTION: Kabuki syndrome is a rare congenital condition characterized clinically by unique facial features, abnormalities in the skeleton, finger pad abnormalities, and developmental delays, as well as a range of other health issues. Existing research lacks information on the daily burden of living with Kabuki syndrome.Entities:
Keywords: Adolescents; Caregivers; Humanistic burden; Kabuki syndrome; Patient burden; Patient research; Survey
Mesh:
Year: 2021 PMID: 34843084 PMCID: PMC8799562 DOI: 10.1007/s12325-021-01953-x
Source DB: PubMed Journal: Adv Ther ISSN: 0741-238X Impact factor: 3.845
Fig. 1Clinical manifestations of Kabuki syndrome (n = 57)
Caregiver-reported demographic and health information (N = 57)
| Characteristic | Characteristics of Kabuki syndrome reported by caregivers ( |
|---|---|
| Genetic testing | |
| Received genetic testing | 54 (94.7%) |
| Mutation | 38 (70.4%) |
| Mutation | 6 (11.1%) |
| Don’t know mutation | 3 (5.6%) |
| Othera | 7 (13.0%) |
| Did not receive genetic testing | 3 (5.3%) |
| Diagnosing clinician | |
| Geneticist | 56 (98.2%) |
| Dysmorphologist | 1 (1.8%) |
| Person with Kabuki syndrome ages 16 and up work status ( | |
| Does not have a job | 7 (87.5%) |
| Has a job | 1 (12.5%) |
| Living situation | |
| Lives at home | 56 (98.2%) |
| Lives outside the home (with assistance) | 1 (1.8%) |
| Educationb | |
| Enrolled in special education public school | 15 (46.9%) |
| Enrolled in traditional public school | 12 (37.5%) |
aOther responses were: clinically diagnosed (n = 2, 3.7%), diagnosis made prior to gene identification (n = 1, 1.9%), have not received results (n = 1, 1.9%), and not positive for either mutation (n = 1, 1.9%)
bBased on responses from caregivers with children older than 5 years (n = 32, 56.1%)
Childhood development
| Characteristic | Age development milestone achieved (years)a | Age developmental milestones are achieved in children with typical development (years) [ | |
|---|---|---|---|
| Average (standard deviation) | Range | Range | |
| Crawl | 1 (0.8) | 0.5–3 | 0.5–0.75 |
| Develop fine motor skills (i.e., grabbing/holding toys) | 1 (1.5) | 0.4–7 | 0.3–0.75 |
| Engage in reciprocal play with others | 4 (3.2) | 0.8–15 | 3–4 |
| Read | 7 (2.0) | 4–13 | 5–7 |
| Sit without assistance | 1 (0.9) | 0.5–5 | 0.5–0.75 |
| Speak | 2 (1.3) | 0.4–5 | 1–1.5 |
| Toilet train | 5 (2.9) | 2–14 | 1.5–3 |
| Walkb | 2 (1.1) | 0–7 | 1–1.5 |
aAge range, average, and standard deviation were calculated on the basis of the total number of comprehensible answers reported by caregivers, and not the total number of respondents. The total number of participants reporting for each characteristic are as follows: crawl (n = 46); develop fine motor skills (n = 55); engage in reciprocal play with others (n = 48); read (n = 21); sit without assistance (n = 54); speak (n = 42); toilet train (n = 24); and walk (n = 44)
bOne participant reported an age of zero for “walk,” but did not specify the age in months
Fig. 2Level of difficulty with certain daily tasks as rated by caregivers (n = 57)
Fig. 3Areas of concern identified by IQ testing as reported by caregivers (n = 27)
Fig. 4Difficult cognitive tasks identified by caregivers (n = 57)
Fig. 5Emotional impacts reported by caregivers (n = 57)
Fig. 6Emotional impacts reported by adolescents (n = 11)
| Kabuki syndrome is a rare genetic condition syndrome characterized by a range of signs and symptoms with an unmet need for treatment. |
| This manuscript details the results of an online survey conducted with 68 participants (57 caregivers of patients with Kabuki syndrome and 11 adolescents with Kabuki syndrome). |
| This work is a novel characterization of Kabuki syndrome from the caregiver and patient perspective. |
| This research was conducted with the intention of collecting patient- and observer-reported data on the burden of disease in Kabuki syndrome in order to help inform the Kabuki syndrome community as well as future clinical trial design. |